|19th May 2017
Image: molecules in a particle-based vaccine for cancer therapy (Flickr: NIH Image Gallery)
**This article originally appeared in PharmaPhorum's Deep Dive magazine - May 2017 edition
With the promise of using the body’s own immune system to fight cancer, immunotherapy has received significant interest from the scientific community, bringing hope to patients across many cancer indications.
The recent development of immunotherapies has led to considerable change in the oncology treatment landscape, driving transformation in the standard of care and yielding lasting responses in patients with metastatic cancers.
While promising, first and second generations of agents have demonstrable weaknesses too, such as:
In order to optimise agent efficacy and overall patient survival, most of these agents are now used in combination. This shift has led to a proliferation of combination studies and approvals, as well as research and commercial partnerships between top pharma companies and small biotechnology companies with innovative product pipelines.
The first generation of agents has shown some interesting results, while also highlighting the limits of immunotherapies in oncology. Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
The second wave of agents encompasses checkpoint inhibitors and cell therapies, among others. Nivolumab, pembrolizumab and atezolizumab are checkpoint inhibitors, meaning that they help the immune system to recognise and kill tumour cells. These three agents have been approved in the US and Europe for multiple indications, where they have shown promising efficacy.
Third-generation agents are emerging. These are a broader set, targeting other aspects of the immune system. They promise multiple therapeutic options that can be tailored to the patient and offer a wide range of possibilities for combination (Hoos et al, 2016).
|11th December 2018
Blue Latitude Health sits down with key opinion leader and specialist neurologist Dr Timothy Vollmer to better understand the paradigm shift in MS treatment. He explains the challenges neurologists face when making treatment decisions, and why patients need to be treated with more efficacious drugs earlier on.
|10th December 2018
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging markets.
|3rd December 2018
Multi-award-winning advocate and patient engagement champion Trishna Bharadia gives a valuable insight into life with multiple sclerosis. She explains how treatment has changed, how our healthcare systems and pharma can unite to improve quality of life for MS patients today, and why her diagnosis isn’t stopping her achieving her goals.